Current Treatment for Gonorrhea
The current recommended first-line treatment for uncomplicated gonorrhea is ceftriaxone 500 mg intramuscularly as a single dose, with doxycycline 100 mg orally twice daily for 7 days added if chlamydial coinfection has not been excluded. 1, 2
Primary Treatment Regimen
The 2021 CDC STI Treatment Guidelines represent a significant update from previous recommendations, increasing the ceftriaxone dose from 250 mg to 500 mg for all uncomplicated urogenital, anorectal, and pharyngeal gonorrhea infections 1, 2. This change reflects evolving antimicrobial stewardship principles and the rising concern about resistance, particularly the rapid increase in azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) 1.
For patients weighing ≥150 kg, the ceftriaxone dose should be increased to 1 gram intramuscularly 3.
Key Components:
- Ceftriaxone 500 mg IM once (1 g if ≥150 kg) 1, 2
- Add doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection not excluded 1, 2
This represents a departure from the 2012-2015 dual therapy approach that routinely included azithromycin 1 g with ceftriaxone 250 mg 4. The shift away from routine azithromycin use addresses antimicrobial stewardship concerns and the drug's impact on commensal organisms, while ceftriaxone MICs have remained stable in the United States with <0.1% exhibiting alert values 1, 2.
Alternative Regimens
When Ceftriaxone is Unavailable:
Cefixime 400 mg orally once PLUS azithromycin 1 g orally once, with mandatory test-of-cure in 1 week 4. However, cefixime is no longer recommended as first-line due to lower and less sustained bactericidal levels compared to ceftriaxone, and limited efficacy for pharyngeal infections 4.
For Severe Cephalosporin Allergy:
Azithromycin 2 g orally once, with mandatory test-of-cure in 1 week 4. This is the only option when cephalosporins cannot be used, though it is suboptimal given rising azithromycin resistance 1.
No Recommended Alternatives for Pharyngeal Infection:
There are currently no recommended alternative therapies for pharyngeal gonorrhea in persons with cephalosporin allergies 1. This represents a critical gap, as pharyngeal infections are more difficult to eradicate and most ceftriaxone treatment failures involve this anatomic site 5.
Treatment Failure Management
If a patient has persistent symptoms or documented treatment failure after the recommended regimen 5:
- Obtain culture and antimicrobial susceptibility testing (not just NAAT) 4
- Report to local/state health department within 24 hours 4
- Consult infectious disease specialist or CDC (404-639-8659) 4
- Consider treatment with gentamicin 240 mg IM once PLUS azithromycin 2 g orally once 5
Alternative salvage regimens from international guidelines include ceftriaxone 1 g IM with azithromycin 2 g orally, or ertapenem 1 g IM for 3 days 5. However, both spectinomycin and gentamicin have poor efficacy for pharyngeal infections, with one study showing only 2 of 10 pharyngeal cases cured with gentamicin 5.
Critical Pitfalls and Caveats
The Pharynx Problem:
Most ceftriaxone treatment failures involve pharyngeal infections, yet many salvage regimens (gentamicin, spectinomycin) have poor pharyngeal efficacy 5. The pharynx may be an important transmission source through kissing, saliva as lubricant, or oral-genital contact 5.
Test-of-Cure Requirements:
- Mandatory for all alternative regimens (cefixime-based, azithromycin monotherapy) 4
- Recommended for all cases per European guidelines to ensure eradication and identify resistance 6
- Should be performed 1 week after treatment using culture when possible, or NAAT if culture unavailable 4
Partner Management:
All sexual partners from the preceding 60 days must be evaluated and treated 4, 7, 4. Expedited partner therapy using cefixime 400 mg plus azithromycin 1 g can be considered for heterosexual partners who cannot be linked to timely evaluation 4.
Pregnancy Considerations:
Pregnant women should receive the same ceftriaxone regimen but must not receive quinolones or tetracyclines 7. If cephalosporin-allergic, options are extremely limited with no good alternatives for pharyngeal infection 1.
Emerging Concerns
The gonorrhea treatment landscape is precarious. Ceftriaxone remains the only highly effective single-dose therapy, with few alternatives and minimal new antimicrobials in development 3, 1. New oral agents gepotidacin and zoliflodacin are in phase 3 trials and pending FDA approval, offering hope for future oral treatment options against multidrug-resistant strains 8.
The capacity for N. gonorrhoeae culture is declining rapidly due to widespread NAAT use, yet culture remains essential for antimicrobial susceptibility testing and resistance surveillance 4. Clinicians must maintain relationships with laboratories capable of performing culture 4.